BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 38759906)

  • 1. Symptoms as a Predictor of the Placebo-Controlled Efficacy of PCI in Stable Coronary Artery Disease.
    Simader FA; Rajkumar CA; Foley MJ; Ahmed-Jushuf F; Chotai S; Bual N; Khokhar A; Gohar A; Lampadakis I; Ganesananthan S; Pathimagaraj RH; Nowbar A; Davies JR; Keeble TR; O'Kane PD; Haworth P; Routledge H; Kotecha T; Spratt JC; Williams R; Nijjer SS; Sen S; Curzen N; Sinha M; Howard JP; Cole G; Harrell FE; Francis DP; Shun-Shin MJ; Al-Lamee RK;
    J Am Coll Cardiol; 2024 Jul; 84(1):13-24. PubMed ID: 38759906
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fractional Flow Reserve and Instantaneous Wave-Free Ratio as Predictors of the Placebo-Controlled Response to Percutaneous Coronary Intervention in Stable Single-Vessel Coronary Artery Disease.
    Al-Lamee R; Howard JP; Shun-Shin MJ; Thompson D; Dehbi HM; Sen S; Nijjer S; Petraco R; Davies J; Keeble T; Tang K; Malik IS; Cook C; Ahmad Y; Sharp ASP; Gerber R; Baker C; Kaprielian R; Talwar S; Assomull R; Cole G; Keenan NG; Kanaganayagam G; Sehmi J; Wensel R; Harrell FE; Mayet J; Thom SA; Davies JE; Francis DP
    Circulation; 2018 Oct; 138(17):1780-1792. PubMed ID: 29789302
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dobutamine Stress Echocardiography Ischemia as a Predictor of the Placebo-Controlled Efficacy of Percutaneous Coronary Intervention in Stable Coronary Artery Disease: The Stress Echocardiography-Stratified Analysis of ORBITA.
    Al-Lamee RK; Shun-Shin MJ; Howard JP; Nowbar AN; Rajkumar C; Thompson D; Sen S; Nijjer S; Petraco R; Davies J; Keeble T; Tang K; Malik I; Bual N; Cook C; Ahmad Y; Seligman H; Sharp ASP; Gerber R; Talwar S; Assomull R; Cole G; Keenan NG; Kanaganayagam G; Sehmi J; Wensel R; Harrell FE; Mayet J; Thom S; Davies JE; Francis DP
    Circulation; 2019 Dec; 140(24):1971-1980. PubMed ID: 31707827
    [TBL] [Abstract][Full Text] [Related]  

  • 4. N-of-1 Trial of Angina Verification Before Percutaneous Coronary Intervention.
    Rajkumar CA; Foley MJ; Ahmed-Jushuf F; Simader FA; Mohsin M; Ganesananthan S; Nowbar AN; Chotai S; Sen S; Petraco R; Nijjer SS; Sehmi J; Ruparelia N; Dungu JN; Kabir A; Tang K; Gamma R; Davies JR; Kotecha T; Cole GD; Howard JP; Keeble TR; Clesham G; O'Kane PD; Harrell FE; Francis DP; Shun-Shin MJ; Al-Lamee RK
    J Am Coll Cardiol; 2024 Jul; 84(1):1-12. PubMed ID: 38752902
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Coronary sinus reducer for the treatment of refractory angina (ORBITA-COSMIC): a randomised, placebo-controlled trial.
    Foley MJ; Rajkumar CA; Ahmed-Jushuf F; Simader FA; Chotai S; Pathimagaraj RH; Mohsin M; Salih A; Wang D; Dixit P; Davies JR; Keeble TR; Cosgrove C; Spratt JC; O'Kane PD; De Silva R; Hill JM; Nijjer SS; Sen S; Petraco R; Mikhail GW; Khamis R; Kotecha T; Harrell FE; Kellman P; Francis DP; Howard JP; Cole GD; Shun-Shin MJ; Al-Lamee RK
    Lancet; 2024 Apr; 403(10436):1543-1553. PubMed ID: 38604209
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Placebo-Controlled Trial of Percutaneous Coronary Intervention for Stable Angina.
    Rajkumar CA; Foley MJ; Ahmed-Jushuf F; Nowbar AN; Simader FA; Davies JR; O'Kane PD; Haworth P; Routledge H; Kotecha T; Gamma R; Clesham G; Williams R; Din J; Nijjer SS; Curzen N; Ruparelia N; Sinha M; Dungu JN; Ganesananthan S; Khamis R; Mughal L; Kinnaird T; Petraco R; Spratt JC; Sen S; Sehmi J; Collier DJ; Sohaib A; Keeble TR; Cole GD; Howard JP; Francis DP; Shun-Shin MJ; Al-Lamee RK;
    N Engl J Med; 2023 Dec; 389(25):2319-2330. PubMed ID: 38015442
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A double-blind randomised placebo-controlled trial of percutaneous coronary intervention for the relief of stable angina without antianginal medications: design and rationale of the ORBITA-2 trial.
    Nowbar AN; Rajkumar C; Foley M; Ahmed-Jushuf F; Howard JP; Seligman H; Petraco R; Sen S; Nijjer SS; Shun-Shin MJ; Keeble TR; Sohaib A; Collier D; McVeigh P; Harrell FE; Francis DP; Al-Lamee RK
    EuroIntervention; 2022 Apr; 17(18):1490-1497. PubMed ID: 35156616
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Percutaneous coronary intervention in stable angina (ORBITA): a double-blind, randomised controlled trial.
    Al-Lamee R; Thompson D; Dehbi HM; Sen S; Tang K; Davies J; Keeble T; Mielewczik M; Kaprielian R; Malik IS; Nijjer SS; Petraco R; Cook C; Ahmad Y; Howard J; Baker C; Sharp A; Gerber R; Talwar S; Assomull R; Mayet J; Wensel R; Collier D; Shun-Shin M; Thom SA; Davies JE; Francis DP;
    Lancet; 2018 Jan; 391(10115):31-40. PubMed ID: 29103656
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reclassification of Treatment Strategy With Instantaneous Wave-Free Ratio and Fractional Flow Reserve: A Substudy From the iFR-SWEDEHEART Trial.
    Andell P; Berntorp K; Christiansen EH; Gudmundsdottir IJ; Sandhall L; Venetsanos D; Erlinge D; Fröbert O; Koul S; Reitan C; Götberg M
    JACC Cardiovasc Interv; 2018 Oct; 11(20):2084-2094. PubMed ID: 30336812
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cardiopulmonary exercise testing and efficacy of percutaneous coronary intervention: a substudy of the ORBITA trial.
    Ganesananthan S; Rajkumar CA; Foley M; Thompson D; Nowbar AN; Seligman H; Petraco R; Sen S; Nijjer S; Thom SA; Wensel R; Davies J; Francis D; Shun-Shin M; Howard J; Al-Lamee R
    Eur Heart J; 2022 Sep; 43(33):3132-3145. PubMed ID: 35639660
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Percutaneous coronary intervention versus medical therapy in patients with angina and grey-zone fractional flow reserve values: a randomised clinical trial.
    Hennigan B; Berry C; Collison D; Corcoran D; Eteiba H; Good R; McEntegart M; Watkins S; McClure JD; Mangion K; Ford TJ; Petrie MC; Hood S; Rocchiccioli P; Shaukat A; Lindsay M; Oldroyd KG
    Heart; 2020 May; 106(10):758-764. PubMed ID: 32114516
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fractional Flow Reserve and Quality-of-Life Improvement After Percutaneous Coronary Intervention in Patients With Stable Coronary Artery Disease.
    Nishi T; Piroth Z; De Bruyne B; Jagic N; Möbius-Winkler S; Kobayashi Y; Derimay F; Fournier S; Barbato E; Tonino P; Jüni P; Pijls NHJ; Fearon WF
    Circulation; 2018 Oct; 138(17):1797-1804. PubMed ID: 30354650
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quality of Life Assessment in Trials of Revascularization for Chronic Stable Angina: Insights from ORBITA and the Implications of Blinding.
    Nowbar AN; Francis DP; Al-Lamee RK
    Cardiovasc Drugs Ther; 2022 Oct; 36(5):1011-1018. PubMed ID: 34417901
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association Between Physiological Stenosis Severity and Angina-Limited Exercise Time in Patients With Stable Coronary Artery Disease.
    Cook CM; Ahmad Y; Howard JP; Shun-Shin MJ; Sethi A; Clesham GJ; Tang KH; Nijjer SS; Kelly PA; Davies JR; Malik IS; Kaprielian R; Mikhail G; Petraco R; Warisawa T; Al-Janabi F; Karamasis GV; Mohdnazri S; Gamma R; de Waard GA; Al-Lamee R; Keeble TR; Mayet J; Sen S; Francis DP; Davies JE
    JAMA Cardiol; 2019 Jun; 4(6):569-574. PubMed ID: 31042268
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of trimetazidine after percutaneous coronary intervention (ATPCI): a randomised, double-blind, placebo-controlled trial.
    Ferrari R; Ford I; Fox K; Challeton JP; Correges A; Tendera M; Widimský P; Danchin N;
    Lancet; 2020 Sep; 396(10254):830-838. PubMed ID: 32877651
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Routine Fractional Flow Reserve Measurement After Percutaneous Coronary Intervention.
    van Bommel RJ; Masdjedi K; Diletti R; Lemmert ME; van Zandvoort L; Wilschut J; Zijlstra F; de Jaegere P; Daemen J; van Mieghem NM
    Circ Cardiovasc Interv; 2019 May; 12(5):e007428. PubMed ID: 31018666
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Coronary physiological assessment combining fractional flow reserve and index of microcirculatory resistance in patients undergoing elective percutaneous coronary intervention with grey zone fractional flow reserve.
    Niida T; Murai T; Yonetsu T; Kanaji Y; Usui E; Matsuda J; Hoshino M; Araki M; Yamaguchi M; Hada M; Ichijyo S; Hamaya R; Kanno Y; Isobe M; Kakuta T
    Catheter Cardiovasc Interv; 2018 Nov; 92(6):1077-1087. PubMed ID: 29516619
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A double-blind, randomised, placebo-controlled trial of the coronary sinus Reducer in refractory angina: design and rationale of the ORBITA-COSMIC trial.
    Foley MJ; Rajkumar CA; Ahmed-Jushuf F; Simader F; Pathimagaraj RH; Nijjer S; Sen S; Petraco R; Clesham G; Johnson T; Harrell FE; Kellman P; Francis D; Shun-Shin M; Howard J; Cole GD; Al-Lamee R
    EuroIntervention; 2024 Feb; 20(3):e216-e223. PubMed ID: 38214677
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Achieving Optimal Medical Therapy: Insights From the ORBITA Trial.
    Foley M; Rajkumar CA; Shun-Shin M; Ganesananthan S; Seligman H; Howard J; Nowbar AN; Keeble TR; Davies JR; Tang KH; Gerber R; O'Kane P; Sharp ASP; Petraco R; Malik IS; Nijjer S; Sen S; Francis DP; Al-Lamee R
    J Am Heart Assoc; 2021 Feb; 10(3):e017381. PubMed ID: 33496201
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The impact of coronary chronic total occlusion percutaneous coronary intervention upon donor vessel fractional flow reserve and instantaneous wave-free ratio: Implications for physiology-guided PCI in patients with CTO.
    Mohdnazri SR; Karamasis GV; Al-Janabi F; Cook CM; Hampton-Till J; Zhang J; Al-Lamee R; Dungu JN; Gedela S; Tang KH; Kelly PA; Davies JE; Davies JR; Keeble TR
    Catheter Cardiovasc Interv; 2018 Sep; 92(3):E139-E148. PubMed ID: 29569332
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.